Abstract

The invention relates to a process for synthesis of a benzophenone or a benzophenone derivative which uses a metal base with a solvent selected from linear or cyclic carboxamides for activating a compound of formula (II) and allowing it to be coupled with a compound of formula (I) so as to give said benzophenone or said benzophenone derivative.

IPC Classes  ?

• C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
• C07D 213/50 - Ketonic radicals
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07C 45/46 - Friedel-Crafts reactions
• C07D 317/54 - Radicals substituted by oxygen atoms

Abstract

xy2z∞233 -33 2-33H-, and –Cl and optionally also substituted at least once by -COO-; where y is 1 to 3; and where z is 0 to 10.

IPC Classes  ?

• G01K 3/04 - Thermometers giving results other than momentary value of temperature giving mean valuesThermometers giving results other than momentary value of temperature giving integrated values in respect of time
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01K 11/20 - Measuring temperature based on physical or chemical changes not covered by group , , , or using thermoluminescent materials

Abstract

The invention relates to a method for recovering uranium from seawater, which uses complexation of uranium and filtration on a membrane made of an inorganic material and which comprises at least the steps of: a) complexing the uranium present in the seawater with at least one water-soluble organic polymer, comprising one or more groups complexing the uranium at the pH of the seawater, the organic polymer being retained by the membrane in the uncomplexed state and in the complexed state; b) passing the water obtained at the end of a) through the membrane, whereby, on either side of the membrane, a uranium-depleted permeate and a uranium-enriched retentate in the form of complexes are obtained; then c) collecting the retentate and dissociating the uranium complexes present in the retentate.

IPC Classes  ?

• C22B 3/20 - Treatment or purification of solutions, e.g. obtained by leaching
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/14 - UltrafiltrationMicrofiltration
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C22B 3/22 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 60/02 - Obtaining thorium, uranium or other actinides
• C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
• C02F 1/66 - Treatment of water, waste water, or sewage by neutralisationTreatment of water, waste water, or sewage pH adjustment
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

The invention relates to a metamaterial comprising at least two components, including a first component that comprises, and preferably consists of, a dielectric oxide of at least one of the elements chosen from among Al, Ti, Ca, Mg, Ta, Hf and Zr; and a second component that comprises, and preferably consists of, a transparent electron-conductive oxide, the oxide being an oxide of at least one element chosen from among Zn, Sn, Ni, Ga, In and Cd, the conductive and dielectric oxides being inert with respect to one another at a temperature of 1000°C and at a pressure of 0.1 MPa, the components being present in the metamaterial in the form of a plurality of layers of the two components or of a wall consisting of one of the components on which a layer of the other component is deposited, the thickness of each layer or wall being less than 300 nanometers and the maximum distance between the two closest walls or layers of the same component being less than 300 nanometers.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• H01L 31/0224 - Electrodes
• H01L 31/0392 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including thin films deposited on metallic or insulating substrates
• H02S 10/30 - Thermophotovoltaic systems
• C23C 16/40 - Oxides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone
• C04B 111/92 - Electrically insulating materials
• C04B 111/94 - Electrically conducting materials

Abstract

A method for extracting at least one lanthanide element, preferably selected from lanthanum (La), praseodymium (Pr), neodymium (Nd), europium (Eu), dysprosium (Dy), and ytterbium (Yb), from a solid material including the lanthanide element, one or more waste elements such as iron (Fe), and/or one or more other lanthanide elements. The method implements a composition including water, at least one organic aprotic solvent, and at least one charged hydrotrope. Also, the use of the composition for recycling lanthanide elements, and more particularly WEEE, and for the decontamination of effluents.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof

Abstract

The invention relates to novel compounds, referred to as pro-ligands or inactivated ligands, of formula (I). The invention also relates to conjugates comprising such pro-ligands, said conjugates corresponding to formula (II). The invention further relates to said conjugates (II) for use as a drug.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools. The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.

IPC Classes  ?

• C07D 303/48 - Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

The present invention relates to as powder composition comprising a specific degradable A and B block copolymer, at least one lubricant, and at least one haemostatic agent. The powder composition according to the invention is particularly useful in a method of preventing and/or treating haemorrhage preferably uterine haemorrhage. The invention also relates to a kit comprising (i) the powder composition of the invention, and (ii) means for inserting said powder composition into a body cavity, preferably into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to novel conjugates having a general formula (I) as defined in claim 1. The conjugates of the invention comprise: 1/ at least one mannose 6-phosphate (M6P) analogue, the M6P analogue targeting both the cation-independent mannose 6-phosphate receptor (CI-MPR) and bone tissue; and 2/ a product of interest Y. The invention also relates to the method for preparing the conjugates and to the therapeutic or diagnostic medical use thereof. The conjugates of formula (I) of the invention are particularly beneficial for use as a medicament, in particular in the treatment of bone diseases and/or diseases affecting both bone tissue and soft tissue.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present application relates to novel bifunctional PROTAC-type compounds simultaneously binding the target protein PXR and E3-ubiquitin ligase, to a method for preparing same, and to uses thereof for treating cancers overexpressing PXR.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07D 235/14 - Radicals substituted by nitrogen atoms

Abstract

The present invention relates to a carbonaceous polymeric material also referred to as porous carbonaceous material complexed with at least one metal ion, preferably a metal cation, a composition comprising a protein immobilized on said material, and methods of preparing the same. The invention further relates to the use of the composition comprising an immobilized protein in particular in heterogeneous biocatalysis applications.

IPC Classes  ?

• C08L 73/00 - Compositions of macromolecular compounds obtained by reactions forming a linkage containing oxygen or oxygen and carbon in the main chain, not provided for in groups Compositions of derivatives of such polymers
• C12N 11/089 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

The present invention relates to a carbon-based polymer material also referred to as a porous carbon-based material complexed with optionally at least one metal ion, preferably a metal cation, and a composition comprising a protein immobilized on said material and methods for preparing same. The invention further relates to the use of the composition comprising an immobilized protein in heterogeneous biocatalysis applications in particular.

IPC Classes  ?

• C12N 11/089 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C08L 73/00 - Compositions of macromolecular compounds obtained by reactions forming a linkage containing oxygen or oxygen and carbon in the main chain, not provided for in groups Compositions of derivatives of such polymers

Abstract

The present invention relates to new amphiphilic perfluorinated compounds and their use as a detergent for extracting membrane-proteins or synthesizing membrane-proteins in acellular system. It also relates to a method for extracting a membrane-protein from a biological sample using such compounds.

IPC Classes  ?

• C11D 1/00 - Detergent compositions based essentially on surface-active compoundsUse of these compounds as a detergent
• C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• C07H 15/06 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical being a hydroxyalkyl group esterified by a fatty acid
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07K 14/245 - Escherichia (G)

Abstract

Disclosed is a light conversion method in which light having a wavelength of 300 nm to 580 nm produced by a light source (1) converting electrical energy into light is subjected to a luminescent material (2) having graphitic-core quantum carbon dots dispersed in a matrix, said quantum carbon dots producing, in response to this illumination, red light having a wavelength of 625 nm to 740 nm.

IPC Classes  ?

• H01L 33/50 - Wavelength conversion elements
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof

Abstract

The present invention relates to a crosslinkable polymer composition comprising at least one calcium phosphate, at least one biocompatible and biodegradable organic polymer or one of its precursors, and Zn-ZnO core-shell particles, to a biomaterial obtainable by photopolymerization of such a crosslinkable polymer composition, to a process for preparing such a composition and such a biomaterial, and to the use of such a biomaterial for various applications in the field of health.

IPC Classes  ?

• A61K 6/62 - Photochemical radical initiators
• A61C 8/02 - Means for transfixation of natural teeth
• A61F 2/28 - Bones
• A61K 6/824 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising transition metal oxides
• A61K 6/887 - Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C01G 9/00 - Compounds of zinc
• C01G 9/02 - OxidesHydroxides
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials

Abstract

The present invention belongs to the field of water purification and decontamination. The present invention relates to new versatile family of trianglamine based compound and their uses thereof as is or in the manufacture of membranes and gels useful to purify and decontaminate water.

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C07D 259/00 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms

Abstract

Respiratory muscle contractile inactivity during mechanical ventilation (MV) induces diaphragm muscle weakness, a condition referred to as ventilator-induced diaphragm dysfunction (VIDD). Among the different hypothesis to explain VIDD, one involves the remodeling of the sarcoplasmic reticulum (SR) calcium release channel/ryanodine receptors (RyR1) in the diaphragm as a proximal mechanism of VIDD. The inventors have developed novel derivatives which prevent with a high efficiency VIDD both in a murine and porcine model of VIDD. This effect is associated with a normalization of RyR function. The present invention thus relates to novel compounds and their use in the treatment of diseases associated with Ryanodine Receptor (RyR) dysfunction.

IPC Classes  ?

• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• C07C 1/00 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon

Abstract

The present invention relates to the use of a compound of formula (I) as a catalyst for the oxidation of an olefin into a ketone and to a process of oxidation of an olefin into a ketone comprising a step (a) of reacting said olefin with an oxidant in the presence of a catalyst of formula (I).

IPC Classes  ?

• C07C 45/36 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties in unsaturated compounds in compounds containing six-membered aromatic rings
• C07C 49/76 - Ketones containing a keto group bound to a six-membered aromatic ring
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony

Abstract

The invention relates to a method of polymerizing at least one fluorinated monomer comprising an ethylene bond, the method comprising putting in contact the at least one fluorinated monomer with a polymerization initiator and a chain transfer agent, the chain transfer agent being a polysulfide compound, preferably a disulfide compound. The invention also relates to a telechelic fluoride-based polymer obtained with said method.

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride

Abstract

The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/36 - Hydroxylated esters of higher fatty acids
• C08G 18/48 - Polyethers
• C08G 18/66 - Compounds of groups , , or
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes
• C09D 175/08 - Polyurethanes from polyethers
• C08L 75/04 - Polyurethanes

Abstract

The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

A method for stripping U(VI) and an An(IV) from an organic solution including tri-n-butyl phosphate in an organic diluent, the solution containing U(VI) and the An(IV) present as U(VI) nitrate and An(IV) nitrate at concentrations such that the U(VI) nitrate concentration is higher than the An(IV) nitrate concentration, and the sum of the U(VI) nitrate and An(IV) nitrate concentrations is ≥55 g/L. The method includes contacting the organic solution and an aqueous solution of nitric and oxalic acids, the oxalic acid concentration in the aqueous solution and the O/A volume ratio selected so that the oxalic acid is deficient with respect to the stoichiometric conditions of a complete precipitation of U(VI) and actinide(IV), to obtain a precipitate containing the actinide(IV) in oxalate form and a fraction of the U(VI) in oxalate form with a U(VI)/actinide(IV) mass ratio of between 0.5 and 5; and separating the precipitate from the organic and aqueous solutions.

IPC Classes  ?

• G21F 9/12 - Processing by absorptionProcessing by adsorptionProcessing by ion-exchange

Abstract

The present invention relates to a compound of the following formula (I): The present invention relates to a compound of the following formula (I): The present invention relates to a compound of the following formula (I): in particular for use in a method for preventing or treating a disease in an individual, more particularly for preventing or treating a disease is associated to progerin or to prelamin A.

IPC Classes  ?

• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07C 271/02 - Carbamic acidsSalts of carbamic acids
• C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a process and an installation wherein a ternary system comprising an aqueous acidic solution, an organic solvent not miscible with water and a thermosensitive hydrotropic agent is used to selectively extract tantalum and optionally niobium by cycling extraction between low- temperature single-phase and high temperature two phase regions in the ternary phase prism far from the critical point.

IPC Classes  ?

• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 34/24 - Obtaining niobium or tantalum
• B01J 38/50 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended using organic liquids
• B01J 38/60 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended using acids
• C01G 33/00 - Compounds of niobium
• C01G 35/00 - Compounds of tantalum

Abstract

The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed oxidation of lignin. It also relates to synthesis of catalyst compounds. The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed oxidation of lignin. It also relates to synthesis of catalyst compounds. The present invention relates to new acridinium-based photoredox catalyst compounds and their use thereof in a chemical reaction, preferably in depolymerisation of lignin models and ultimately lignin. The invention also relates to the method of synthesis of the new acridinium-based photoredox catalyst compounds according to the invention.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C07D 219/02 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/085 - Organic compound
• C25D 3/38 - ElectroplatingBaths therefor from solutions of copper
• C25D 5/10 - Electroplating with more than one layer of the same or of different metals
• C25D 5/34 - Pretreatment of metallic surfaces to be electroplated
• C25D 5/48 - After-treatment of electroplated surfaces

Abstract

2222 to small molecules and in particular ethylene.

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/085 - Organic compound
• C25D 3/38 - ElectroplatingBaths therefor from solutions of copper
• C25D 5/10 - Electroplating with more than one layer of the same or of different metals
• C25D 5/34 - Pretreatment of metallic surfaces to be electroplated
• C25D 5/48 - After-treatment of electroplated surfaces
• C25D 5/00 - Electroplating characterised by the processPretreatment or after-treatment of workpieces
• C25D 7/00 - Electroplating characterised by the article coated

Abstract

The invention relates to a scintillator material and to a method for producing a scintillator material (3) comprising carbon quantum dots with a graphitic core and dispersed in a matrix, said material comprising aromatic units capable of emitting UV radiation in response to irradiation, in particular of the beta type, said UV radiation causing luminescence of the carbon dots and the emission by same of radiation in the visible domain.

IPC Classes  ?

• G01T 1/00 - Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
• G21K 4/00 - Conversion screens for the conversion of the spatial distribution of particles or ionising radiation into visible images, e.g. fluoroscopic screens
• H01L 27/146 - Imager structures
• C01B 32/15 - Nanosized carbon materials
• C09K 11/65 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing carbon

Abstract

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Abstract

The invention relates to the use of a composition comprising at least one derivative compound which is derived from cashew nut shell oil (CNSL) and which has at least one ester function and/or at least one epoxide function, as a plasticizer for cellulose acetate, for the preparation of a plastic material comprising or consisting of cellulose acetate.

IPC Classes  ?

• C08K 5/00 - Use of organic ingredients
• C08K 5/103 - EstersEther-esters of monocarboxylic acids with polyalcohols
• C08K 5/105 - EstersEther-esters of monocarboxylic acids with phenols
• C08K 5/134 - Phenols containing ester groups
• C08K 5/1515 - Three-membered rings
• C07C 39/00 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 69/157 - Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
• C07D 303/14 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
• C07D 303/38 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 303/40 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
• C07C 69/86 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
• C07C 69/54 - Acrylic acid estersMethacrylic acid esters

IPC Classes  ?

• C01G 53/00 - Compounds of nickel
• H01M 4/00 - Electrodes

Abstract

The present invention relates to a lithium manganese-based oxide positive electrode active material comprising an outer layer of Al for lithium-ion secondary batteries (LIBs) suitable for electric vehicle (EV) and hybrid electric vehicle (HEV) applications.

IPC Classes  ?

• C01G 53/00 - Compounds of nickel
• H01M 4/00 - Electrodes

Abstract

The invention relates mainly to a biobased polyurethane resin composition which is essentially characterized in that it is obtained by mixing a volume V1 of polyisocyanate phase, and a volume V2 of polyol phase, and in that: either the polyisocyanate phase comprises at least two polyisocyanates which each comprise at least 25% of biobased carbons, and the polyol phase comprises at least one polyol which comprises at least 80% of biobased carbons, or the polyol phase comprises at least two polyols which each comprise at least 80% of biobased carbons, and the polyisocyanate phase comprises at least one polyisocyanate which comprises at least 25% of biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition which advantageously involves the evaluation of the equivalent volumes of reactive function of each compound. The invention lastly relates to a printed support covered at least partly with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/24 - Catalysts containing metal compounds of tin
• C08G 18/48 - Polyethers
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/78 - Nitrogen
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes

Abstract

The invention relates mainly to a biobased polyurethane resin composition which is essentially characterized in that it is obtained by mixing a volume V1 of polyisocyanate phase, and a volume V2 of polyol phase, and in that: either the polyisocyanate phase comprises at least two polyisocyanates which each comprise at least 25% of biobased carbons, and the polyol phase comprises at least one polyol which comprises at least 80% of biobased carbons, or the polyol phase comprises at least two polyols which each comprise at least 80% of biobased carbons, and the polyisocyanate phase comprises at least one polyisocyanate which comprises at least 25% of biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition which advantageously involves the evaluation of the equivalent volumes of reactive function of each compound. The invention lastly relates to a printed support covered at least partly with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/24 - Catalysts containing metal compounds of tin
• C08G 18/48 - Polyethers
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/78 - Nitrogen
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes

Abstract

The present disclosure relates to the field of devices for the draining urine that are attached to the penis of a patient, in particular a patient with urinary incontinence, without a medical glue or adhesive. Said device comprises a balanic sheath and an attachment system (100), wherein the balanic sheath comprises a proximal portion, the proximal portion of the balanic sheath having a frustoconical inner surface and an outer surface each comprising a distal end having a small diameter (Dd) and a proximal end having a large diameter (Dp), wherein the attachment system (100) is configured to hold the retracted foreskin on the outer surface of the proximal portion, the balanic sheath comprising a distal portion extending the proximal portion with an outer surface having a protrusion (B), such that the retracted foreskin is held by the attachment system (100) between the proximal portion and the distal portion.

IPC Classes  ?

• A61F 5/453 - Genital receptacles for collecting urine or other discharge from male member

Abstract

The present disclosure relates to the field of devices for the draining urine that are attached to the penis of a patient, in particular a patient with urinary incontinence, without a medical glue or adhesive. Said device comprises a balanic sheath and an attachment system (100), wherein the balanic sheath comprises a proximal portion, the proximal portion of the balanic sheath having a frustoconical inner surface and an outer surface each comprising a distal end having a small diameter (Dd) and a proximal end having a large diameter (Dp), wherein the attachment system (100) is configured to hold the retracted foreskin on the outer surface of the proximal portion, the balanic sheath comprising a distal portion extending the proximal portion with an outer surface having a protrusion (B), such that the retracted foreskin is held by the attachment system (100) between the proximal portion and the distal portion.

IPC Classes  ?

• A61F 5/453 - Genital receptacles for collecting urine or other discharge from male member

Abstract

The invention relates to a method of polymerizing at least one monomer comprising a vinylidene fluoride monomer, the method comprising putting in contact the at least one monomer with a polymerization initiator -and an oxidizing agent, the polymerization initiator having the formula (I): The invention relates to a method of polymerizing at least one monomer comprising a vinylidene fluoride monomer, the method comprising putting in contact the at least one monomer with a polymerization initiator -and an oxidizing agent, the polymerization initiator having the formula (I): The invention relates to a method of polymerizing at least one monomer comprising a vinylidene fluoride monomer, the method comprising putting in contact the at least one monomer with a polymerization initiator -and an oxidizing agent, the polymerization initiator having the formula (I): wherein Rf is a fluoroalkyl group comprising from 1 to 3 carbon atoms; and Mx+ is chosen from a monovalent cation, or a divalent cation, or a trivalent cation, or a tetravalent cation.

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride
• C08F 14/28 - Hexafluoropropene
• C08F 16/24 - Monomers containing halogen
• C08F 4/46 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides selected from alkali metals

Abstract

A dry formulation obtained by desiccation of an emulsion comprises at least one surfactant, at least one lipophilic compound, and at least one metal catalyst. The dry formulation may be used to carry out a catalysed reaction in an aqueous medium. The dry formulation has a water content of less than (10) wt% relative to the total weight of the dry formulation, and wherein: - the at least one surfactant is selected from the group comprising dendrimers of Dendri-TAC type, oligomers of F,TACn or H,TACn type, TPGS 1000, TPGS 750 M, surfactants derived from sugars and/or amino acids, and combinations thereof; - the at least one lipophilic compound is selected from the group comprising lipids, hydrophobic complexing agents and combinations thereof; and - the metal catalyst comprises a metal selected from Groups (3) to (12) of the Periodic Table.

IPC Classes  ?

• B01J 31/06 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 31/22 - Organic complexes

Abstract

A method for manufacturing a part made of composite material in which an adhesion promoter is grafted to a coating present on the fibre surface as well as to a ceramic precursor resin. Afterwards, a ceramic matrix phase is formed in the porosity of the fibre preform by pyrolysis of the polymerised resin.

IPC Classes  ?

• C04B 41/45 - Coating or impregnating

Abstract

2 the bond to the second macromolecular chain.

IPC Classes  ?

• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
• C04B 35/626 - Preparing or treating the powders individually or as batches
• C04B 35/628 - Coating the powders
• C04B 35/64 - Burning or sintering processes
• C08G 79/08 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing boron
• C08G 77/62 - Nitrogen atoms
• C04B 35/632 - Organic additives

Abstract

The present invention relates to novel degradable branched-block copolymers, comprising a star-shaped copolymer central core or a linear copolymer central core, functionalized with photoreactive groups chosen among aryl-azide, (meth)acrylate or thiol groups. The present invention also relates to the use of these degradable branched-block copolymers as photo-crosslinkers to provide degradable photo-crosslinked elastomers as biomaterials suitable for medical and tissue engineering applications. A method for preparing a degradable photo-crosslinked polymer, preferably a degradable photo-crosslinked elastomer, starting from the branched-block copolymer of the invention via a shaping process and an irradiation step is also provided.

IPC Classes  ?

• C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules

Abstract

The invention relates to a process for liquid-liquid extraction of at least one salt of a metal selected from elements from the rare earths group and from the actinides group from an acidic aqueous phase containing them, said process comprising in particular a step of mixing an acidic aqueous phase comprising said salt of said metal and at least one non-ionic hydrotrope with an organic phase comprising at least one non-ionic hydrotrope and at least one extractant.

IPC Classes  ?

• C01F 17/17 - Preparation or treatment, e.g. separation or purification involving a liquid-liquid extraction
• C01G 43/00 - Compounds of uranium

Abstract

The present invention relates to a method for extracting at least one lanthanide element, preferably selected from lanthanum (La), praseodymium (Pr), neodymium (Nd), europium (Eu), dysprosium (Dy), and ytterbium (Yb), from a solid material comprising said lanthanide element, one or more waste elements such as iron (Fe), and/or one or more other lanthanide elements, the method implementing a composition comprising water, at least one organic aprotic solvent, and at least one charged hydrotrope, and the use of said composition for recycling lanthanide elements, and more particularly WEEE, and for the decontamination of effluents.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes

Abstract

The present invention relates to an insulating panel (1) based on composite materials, characterised in that it comprises at least: - a layer (2) comprising a mixture of at least one binder and cork, and - a planar or profiled metal sheet (3).

IPC Classes  ?

• E04F 13/08 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elementsSub-structures thereforFastening means therefor composed of a plurality of similar covering or lining elements
• E04F 13/10 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elementsSub-structures thereforFastening means therefor composed of a plurality of similar covering or lining elements of wood
• E04F 13/16 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elementsSub-structures thereforFastening means therefor composed of a plurality of similar covering or lining elements of fibres or chips, e.g. bonded with synthetic resins
• E04F 13/18 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elementsSub-structures thereforFastening means therefor composed of a plurality of similar covering or lining elements of organic plastics with or without reinforcements or filling materials

Abstract

The invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly(oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly(oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The subject of the invention is a degradable intrauterine system for the release of a haemostatic agent into the uterine cavity, comprising a degradable copolymer-based polymer matrix comprising at least one A and B block copolymer, and a haemostatic agent intended for release into the uterine cavity, wherein: block A is a polyester; block B is a poly(oxyethylene) (PEO); the weight-average molecular mass of the blocks B is greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit mole ratio is between 0.5 and 5. The invention also relates to a haemostatic agent for use in the treatment of uterine haemorrhage, wherein the haemostatic agent is delivered into the intrauterine cavity by means of a degradable intrauterine system according to the invention.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The present invention relates to a star-shaped polymer M comprising a central core and n arms attached to the core, wherein each arm is a polymer chain comprising at least one polymer PI, wherein n is an integer greater than or equal to 4, characterized in that each polymer chain is independently functionalized at its end by a group G chosen from a (meth)acrylate group, a catechol derivative, a phenylboronic acid derivative and a pyrogallolyl group, on condition that at least one polymer chain is functionalized at its end by a catechol derivative, a phenylboronic acid derivative or a pyrogallolyl group. The present invention also relates to a crosslinked polymer obtained by crosslinking at least one star-shaped polymer M as defined above, and the use thereof as self-healing material and/or as bioadhesive material, notably as surgical glue or as a medical device or in a medical device. The present invention also relates to a method for correcting a defect of a material comprising, notably consisting essentially of, a crosslinked polymer according to the invention.

IPC Classes  ?

• C08G 65/332 - Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides or esters thereof
• C08G 65/334 - Polymers modified by chemical after-treatment with organic compounds containing sulfur
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen
• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds

Abstract

The invention relates to a supramolecular nanotube comprising at least one single-chain magnet including a coordination polymer, said coordination polymer comprising at least one linear macromolecular chain comprising repeating units containing at least one metal, said metal being coordinated by at least one ligand comprising at least one linear carbon chain, said linear carbon chain comprising more than 5 carbons, preferably the linear carbon chain comprises 6 to 30 carbons.

IPC Classes  ?

• C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic

Abstract

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.

IPC Classes  ?

• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61P 25/16 - Anti-Parkinson drugs
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 35/00 - Antineoplastic agents
• C07D 303/48 - Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.

IPC Classes  ?

• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 35/00 - Antineoplastic agents
• C07C 243/34 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
• C07D 203/08 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
• C07D 303/48 - Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 5/06 - Dipeptides
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

Cumene hydroperoxide oligomer according to Formula (I): 4—, wherein X is absent if Q is absent, and wherein the substitution on the aromatic compound is effected in position 2, 3 or 4 relative to the cumene hydroperoxide group; and n is a value from 1 to 50.

IPC Classes  ?

• C08F 222/24 - Esters containing sulfur
• A61K 6/17 - Particle size
• A61K 6/71 - Fillers
• A61K 6/79 - Initiators
• A61K 6/816 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising titanium oxide
• A61K 6/818 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising zirconium oxide
• A61K 6/887 - Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C08F 4/40 - Redox systems

Abstract

The present application relates to novel bifunctional PROTAC-type compounds simultaneously binding the target protein PXR and E3-ubiquitin ligase, to a method for preparing same, and to uses thereof for treating cancers overexpressing PXR.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present application relates to novel bifunctional PROTAC-type compounds simultaneously binding the target protein PXR and E3-ubiquitin ligase, to a method for preparing same, and to uses thereof for treating cancers overexpressing PXR.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents
• C07D 235/14 - Radicals substituted by nitrogen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention relates to new amphiphilic perfluorinated compounds and their use as a detergent for extracting membrane-proteins or synthesizing membrane-proteins in acellular system. It also relates to a method for extracting a membrane-protein from a biological sample using such compounds.

IPC Classes  ?

• C07H 15/06 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical being a hydroxyalkyl group esterified by a fatty acid
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C11D 1/00 - Detergent compositions based essentially on surface-active compoundsUse of these compounds as a detergent
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine
• C07C 23/02 - Monocyclic halogenated hydrocarbons
• C07C 25/13 - Monocyclic aromatic halogenated hydrocarbons containing fluorine
• C07C 291/04 - Compounds containing carbon and nitrogen and having functional groups not covered by groups containing nitrogen-oxide bonds containing amino-oxide bonds
• C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Abstract

The invention relates to the field of biomimetic membranes with artificial water channels, notably the use thereof in the context of the production and management of drinking water. The present invention relates to a biomimetic membrane with artificial water channels, the method of synthesis thereof, as well as the use thereof for desalination of brackish water and seawater, production of ultra-pure water or filtration of contaminants.

IPC Classes  ?

• B01D 71/56 - Polyamides, e.g. polyester-amides
• B01D 69/12 - Composite membranesUltra-thin membranes
• C08L 77/06 - Polyamides derived from polyamines and polycarboxylic acids

Abstract

p present, xp is independently from about 0 to about 60; y is from about 0 to about 60; z is from about 0 to about 60; m is from about 0 to about 40; and n is zero or nonzero. At least one of y and z is nonzero when p is zero, and p is nonzero when y and z are both zero.

IPC Classes  ?

• C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
• B01D 63/06 - Tubular membrane modules
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 69/04 - Tubular membranes
• B01D 69/10 - Supported membranesMembrane supports
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 71/02 - Inorganic material
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C04B 35/01 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides
• C04B 35/16 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silicates other than clay
• C04B 35/48 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zirconium or hafnium oxides or zirconates or hafnates
• C04B 35/571 - Fine ceramics obtained from polymer precursors
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

The invention relates to a method of polymerizing at least one fluorinated monomer comprising an ethylene bond, the method comprising putting in contact the at least one fluorinated monomer with a polymerization initiator and a chain transfer agent, the chain transfer agent being a polysulfide compound, preferably a disulfide compound. The invention also relates to a telechelic fluoride-based polymer obtained with said method.

IPC Classes  ?

• C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
• C08F 114/22 - Vinylidene fluoride
• C08F 214/22 - Vinylidene fluoride
• C08F 14/18 - Monomers containing fluorine

Abstract

The present invention relates to the use of a fluorinated copolymer in the manufacture of a solid polymer film, to give said film properties of adhesion to a metal surface or to glass. It also relates to a process for improving the adhesion of a fluoropolymer to a metal, polymer or glassy substrate, and also to a composite part comprising a solid polymer film in direct contact with at least one metal or glassy element.

IPC Classes  ?

• C08F 214/22 - Vinylidene fluoride
• C09D 127/16 - Homopolymers or copolymers of vinylidene fluoride
• C08L 43/02 - Homopolymers or copolymers of monomers containing phosphorus
• B32B 27/24 - Layered products essentially comprising synthetic resin characterised by the use of special additives using solvents or swelling agents
• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
• B32B 15/20 - Layered products essentially comprising metal comprising aluminium or copper
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• B32B 15/082 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising vinyl resinsLayered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising acrylic resins
• B32B 27/22 - Layered products essentially comprising synthetic resin characterised by the use of special additives using plasticisers
• B32B 7/04 - Interconnection of layers
• B32B 15/085 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising polyolefins
• B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
• B32B 27/06 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance
• B32B 17/10 - Layered products essentially comprising sheet glass, or fibres of glass, slag or the like comprising glass as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 15/18 - Layered products essentially comprising metal comprising iron or steel
• B32B 27/20 - Layered products essentially comprising synthetic resin characterised by the use of special additives using fillers, pigments, thixotroping agents
• B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups

Abstract

Disclosed herein are novel copolymers of poly(ε-caprolactone) (PCL) and polydopamine (PDA), optionally further comprising a PEG chain, methods for making them as well as their use in pharmaceutical preparations, especially implants or in situ gelling depots, for the treatment of ocular disorders or eye diseases.

IPC Classes  ?

• C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen
• C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C08G 63/682 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing halogens
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The invention relates to the use of a mixture of quaternary ammonium salts as an extractant for extracting uranium(VI) from an aqueous sulfuric acid solution. It also relates to mixtures of quaternary ammonium salts and to a method enabling recovery of the uranium(VI) present in an aqueous sulfuric acid solution from the leaching of a uranium-bearing ore using sulfuric acid and utilizing a mixture of quaternary ammonium salts as an extractant. Applications: treatment of uranium-bearing ores (uraninite, pitchblende, coffinite, brannerite, carnotite, etc.) for the purpose of utilizing the uranium(VI) present in these ores.

IPC Classes  ?

• C22B 3/28 - Amines
• C22B 3/40 - Mixtures
• C22B 60/02 - Obtaining thorium, uranium or other actinides

Abstract

The invention relates to a method for recovering rare earth metals and uranium(VI) present in an aqueous phosphoric acid solution by liquid-liquid extraction that enables not only highly efficient co-extraction of the rare earth metals and the uranium(VI) from this aqueous solution but also subsequent selective recovery of the rare earth metals and of the uranium(VI). Applications: treatment of aqueous solutions from the leaching of natural phosphates by sulfuric acid in order to utilize the rare earth metals and uranium(VI) present in these aqueous solutions.

IPC Classes  ?

• C22B 3/38 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds containing phosphorus
• C22B 59/00 - Obtaining rare earth metals
• C22B 60/02 - Obtaining thorium, uranium or other actinides
• C22B 3/28 - Amines

Abstract

The present invention relates to a compound of the following formula (I) in particular for use in a method for preventing or treating a disease in an individual, more particularly for preventing or treating a disease is associated to progerin or to prelamin A.

IPC Classes  ?

• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

The present invention relates to a compound of the following formula (I) in particular for use in a method for preventing or treating a disease in an individual, more particularly for preventing or treating a disease is associated to progerin or to prelamin A.

IPC Classes  ?

• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

2222 to small molecules.

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/07 - Oxygen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/065 - Carbon
• C25B 11/085 - Organic compound
• C25D 3/38 - ElectroplatingBaths therefor from solutions of copper
• C25D 3/46 - ElectroplatingBaths therefor from solutions of silver

Abstract

A process for manufacturing a polybenzoxazine monomer, crosslinking the latter, and using the crosslinked product to form an ablative thermal protection system for a thruster nozzle or atmospheric reentry body.

IPC Classes  ?

• C07D 265/16 - 1,3-OxazinesHydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
• C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C08G 73/02 - Polyamines

Abstract

The present invention relates to a microfluidic chip for attracting and destroying a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element at least one network of microchannels (2) arranged between the reservoir (1) and the external environment (3) of the chip and allowing the chemoattractant compound to pass to said environment and the biological element present in said environment to pass to the reservoir (1) at least one electrode (4) arranged between the reservoir (1) and the network of microchannels (2) or at the same location as the network of microchannels (2), said electrode (4) being capable of generating an electric field so as to destroy the biological element during its passage to the reservoir (1).

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed oxidation of lignin. It also relates to synthesis of catalyst compounds. The present invention relates to new acridinium-based photoredox catalyst compounds and their use thereof in a chemical reaction, preferably in depolymerisation of lignin models and ultimately lignin. The invention also relates to the method of synthesis of the new acridinium-based photoredox catalyst compounds according to the invention.

IPC Classes  ?

• C07D 219/02 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Abstract

The present invention belongs to the field of catalytic chemistry, and more specifically to catalysed oxidation of lignin. It also relates to synthesis of catalyst compounds. The present invention relates to new acridinium-based photoredox catalyst compounds and their use thereof in a chemical reaction, preferably in depolymerisation of lignin models and ultimately lignin. The invention also relates to the method of synthesis of the new acridinium-based photoredox catalyst compounds according to the invention.

IPC Classes  ?

• C07D 219/02 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Abstract

Pyrococcus horikoshiiArchaeaPyrococcus horikoshiiArchaeaPyrococcus horikoshiiPyrococcus horikoshii OT3, or its homologs from hyperthermophilic Archaea, to a process for producing sulfated glycosaminoglycans (GAGs), and to sulfated glycosaminoglycans obtained by the process and their use for producing pharmaceutical, cosmetic, nutraceutical or food products.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/10 - Transferases (2.)
• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: —providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; —the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: —a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilization of the emulsion.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• B01D 11/02 - Solvent extraction of solids

Abstract

The present invention relates to new compounds that act as inhibitors of metallo-beta-lactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of bacterial infections. More generally, the present invention finds applications in any field wherein bacteria producing MBL must be removed.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/433 - Thiadiazoles
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The present invention relates to the manufacture of a part made of composite material, the matrix of which is at least partially formed by pyrolysis of a hybrid cross-linked copolymer producing a matrix having a low free carbon content and enhanced properties.

IPC Classes  ?

• C04B 35/571 - Fine ceramics obtained from polymer precursors
• C04B 35/589 - Fine ceramics obtained from polymer precursors
• C04B 35/626 - Preparing or treating the powders individually or as batches
• C04B 35/632 - Organic additives
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
• C08G 77/60 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which all the silicon atoms are connected by linkages other than oxygen atoms
• C08G 77/62 - Nitrogen atoms
• C08G 79/08 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing boron
• C08G 79/10 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing aluminium
• C08L 83/16 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon onlyCompositions of derivatives of such polymers in which all the silicon atoms are connected by linkages other than oxygen atoms

Abstract

The invention relates to a method for manufacturing a part made of composite material in which an adhesion promoter is grafted to a coating present on the fibre surface as well as to a ceramic precursor resin. Afterwards, a ceramic matrix phase is formed in the porosity of the fibre preform by pyrolysis of the polymerised resin (40).

IPC Classes  ?

• C04B 35/571 - Fine ceramics obtained from polymer precursors
• C04B 35/589 - Fine ceramics obtained from polymer precursors
• C04B 35/626 - Preparing or treating the powders individually or as batches
• C04B 35/628 - Coating the powders
• C04B 35/632 - Organic additives
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like

Abstract

A dry formulation obtained by desiccation of an emulsion comprises at least one surfactant, at least one lipophilic compound, and at least one metal catalyst. The dry formulation may be used to carry out a catalysed reaction in an aqueous medium. The dry formulation has a water content of less than (10) wt% relative to the total weight of the dry formulation, and wherein: - the at least one surfactant is selected from the group comprising dendrimers of Dendri-TAC type, oligomers of F,TACn or H,TACn type, TPGS 1000, TPGS 750M, surfactants derived from sugars and/or amino acids, and combinations thereof; - the at least one lipophilic compound is selected from the group comprising lipids, hydrophobic complexing agents and combinations thereof; and - the metal catalyst comprises a metal selected from Groups (3) to (12) of the Periodic Table.

IPC Classes  ?

• B01J 31/06 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
• B01J 31/22 - Organic complexes
• B01J 31/24 - Phosphines
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/32 - Freeze drying, i.e. lyophilisation
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves

Abstract

An emulsion for therapeutic use through controlled drug release comprises a discontinuous phase comprising droplets, including a mixture of lipophilic compounds, at least one surfactant and at least one drug, and a continuous aqueous phase. The mixture of lipophilic compounds comprises a first lipophilic compound having a first mass solubility in water and a second lipophilic compound having a second mass solubility in water lower than the first mass solubility, in a volumetric ratio, of the first lipophilic compound to the second lipophilic compound, which is greater than 70: 30.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Abstract

f22 -xxMx+ff is a fluoroalkyl group comprising from 1 to 3 carbon atoms; and Mx+ is chosen from a monovalent cation, or a divalent cation, or a trivalent cation, or a tetravalent cation.

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride
• C08F 114/22 - Vinylidene fluoride
• C08F 214/22 - Vinylidene fluoride
• C08F 4/40 - Redox systems
• C08F 2/16 - Aqueous medium

Abstract

4,3 of between 0.5 pm and 5.5 pm, and the at least one perfluorocarbon compound has a boiling point above 100° C. The present description also relates to methods comprising administering such an injectable emulsion in, for example, ultrasound ablation surgery (FIG. 3).

IPC Classes  ?

• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 49/10 - Organic compounds
• A61N 7/00 - Ultrasound therapy

Abstract

The present invention relates to a porous material comprising metal oxide nanoparticles, which are adsorbed by a glass foam support and/or a glass ceramic foam support, for applications in heterogeneous catalysis in a liquid and/or gaseous phase.

IPC Classes  ?

• B01J 23/34 - Manganese
• B01J 35/10 - Solids characterised by their surface properties or porosity

Abstract

The present invention relates to a method for recovering one or more metals M chosen from gold and metals from the platinum group contained in an acidic aqueous phase A1, said method comprising the following steps: (1) extracting the metal(s) M from the acidic aqueous phase A1, said step comprising the following steps (1a) and (1b): (1a) bringing the acidic aqueous phase A1 into contact with a water-immiscible phase A2, whereby, after phase separation, an aqueous phase A1' and a phase A2' comprising the metal(s) M are obtained; subsequently (1b) collecting the phase A2'. (2) recovering the metal(s) M present in the phase A2' as obtained at the end of step (1b). The phase A2 is chosen from a phase A21 comprising a malonamide and an ionic liquid LI, and a phase A22 comprising a functionalised ionic liquid LIF comprising a malonamide group and the recovery step (2) is chosen from: (2') electroplating, and (2") back-extracting, excluding recovering, only the palladium as the metal M when the phase A2 consists of the phase A21.

IPC Classes  ?

• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 11/00 - Obtaining noble metals
• C22B 3/40 - Mixtures

Abstract

2. The process according to the invention can be implemented in particular in a closed reactor or a semi-closed reactor or a continuous reactor, electrochemically assisted or not.

IPC Classes  ?

• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a vascularised cardiac organoid model comprising cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM) grafted onto a chorioallantoic membrane of a fertilised egg. The present invention also relates to a method for obtaining the vascularised cardiac organoid model. The present intention also relates to a method for characterising the activity of a compound relative to the vascularised cardiac organoid model. The present invention also relates to a kit comprising the vascularised cardiac organoid model.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The invention relates to the use of an organometallic salt of nitroprusside as an NO-releasing agent, a composite material comprising such an organometallic salt of nitroprusside, an implant comprising such an organometallic salt of nitroprusside and a method for manufacturing this organometallic salt of nitroprusside. It also relates to a method for releasing NO and a method for decontaminating a substrate which is suspected of being contaminated with bacteria. The organometallic salt of nitroprusside used in the invention has the following formula I: MII[FeII522Ο formula I, where Mn represents ZnIIor FeII, and 2 ≤ x ≤ 18. The invention can be used in the medical field in particular.

IPC Classes  ?

• C07F 15/02 - Iron compounds
• A61K 6/842 - Rare earth metals
• A61K 31/295 - Iron group metal compounds
• B29C 70/00 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts

Abstract

The invention relates to a bio-based polyester resin comprising a mixture of diols and polyacids, to a process for the preparation thereof, and to a film-forming composition and a nail polish comprising said resin. The polyester resin can be used in particular as a binder in a nail polish.

IPC Classes  ?

• C08G 18/32 - Polyhydroxy compoundsPolyaminesHydroxy amines
• C08G 63/672 - Dicarboxylic acids and dihydroxy compounds

Abstract

The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.

IPC Classes  ?

• C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 39/06 - Free radical scavengers or antioxidants

Abstract

A continuous, solvent-free and non-enzymatic method for synthesizing a compound of formula (I): Ra-POLYPEP-Rc (I) wherein: POLYPEP is a poly-amino acid compound, Ra and Rc are as specified, the method including the steps of: a) feeding an extrusion reactor with (1) a compound of formula (II) Ra-PEPNt-Rg (II) wherein; PEPNt is a mono- or a poly-amino acid compound, Ra and Rg are as specified, and (2) a compound of formula (III) H-PEPCt-Rc (III) wherein: PEPCt is a mono- or a poly-amino acid compound, and Rc is as defined in the absence of any solvent, so that the compound of formula (II) and the compound of formula (III) react together for generating a compound of formula (I), and b) collecting the compound of formula (I) from the extrusion reactor.

IPC Classes  ?

• C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents
• B29C 48/395 - Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
• B29C 48/40 - Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws, e.g. twin screw extruders

Abstract

A process for manufacturing a cross-linked product has improved charring and thermal stability properties in which there is cross-linking of a benzoxazine monomer.

IPC Classes  ?

• C08G 73/22 - Polybenzoxazoles
• B64G 1/14 - Space shuttles
• B64G 1/40 - Arrangements or adaptations of propulsion systems

Abstract

The invention relates to the field of biomimetic membranes with artificial water channels, in particular the use thereof in the context of the production and management of drinking water. The present invention relates to a biomimetic membrane with artificial water channels, the method of synthesising same, and the use thereof for desalinating brackish water and sea water, obtaining ultra-pure water or filtering pollutants.

IPC Classes  ?

• B01D 69/10 - Supported membranesMembrane supports
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 71/56 - Polyamides, e.g. polyester-amides

Abstract

The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

2 and the stiffness of the network includes an elastic modulus between 0.01 and 10,000 kPa.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C08L 33/18 - Homopolymers or copolymers of nitriles
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• D01D 5/00 - Formation of filaments, threads, or the like
• D01D 10/02 - Heat treatment
• D01F 6/18 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of unsaturated nitriles, e.g. polyacrylonitrile, polyvinylidene cyanide
• D06M 15/15 - Proteins or derivatives thereof

Abstract

The present invention relates to a microfluidic chip for attracting and destroying a specific biological element, said chip comprising: - a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element; - at least one set of microchannels (2) arranged between the reservoir (1) and the external environment (3) of the chip and allowing the chemoattractant compound to move toward said medium and the biological element present in said medium to move in the direction of the reservoir (1); - at least one electrode (4) arranged between the reservoir (1) and the set of microchannels (2) or at the same location as the set of microchannels (2), said electrode (4) being capable of generating an electric field so as to destroy the biological element as it moves toward the reservoir (1).

IPC Classes  ?

• A61N 1/40 - Applying electric fields by inductive or capacitive coupling

Abstract

The present invention relates to novel degradable branched-blockcopolymers, comprising a star-shaped copolymer central core or a linear copolymer central core, functionalized with photoreactive groups chosen among aryl-azide, (meth)acrylate or thiol groups. The present invention also relates to the use of these degradable branched-block copolymers as photo- crosslinkersto provide degradable photo-crosslinkedelastomers as biomaterials suitable for medical and tissue engineering applications. A method for preparinga degradable photo- crosslinked polymer, preferably a degradable photo-crosslinked elastomer,starting from the branched-block copolymer of the invention via a shaping process and an irradiation step is also provided.

IPC Classes  ?

• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen
• C08G 63/664 - Polyesters containing oxygen in the form of ether groups derived from hydroxycarboxylic acids

Abstract

The inventions relates to novel arylsulfonamides of 2-aryl-2,5-dihydro-7H-pyrrole-3-carboxamide derivatives of general formula (I): A wherein: Ar represent 5-6 membered aromatic/heteroaromatic ring optionally substituted with halogen atoms, an alkyl group substituted with one or more halogen atoms, or C1-C2 alkoxy group; A represents unsubstituted aryl (5-6 membered), biaryl (8-10 membered), heteroaryl (5-6 membered), heteroaryl (8- 10 membered) having 1 or 2 heteroatoms independently selected from the group consisting of N or S, optionally substituted with one or more substituents selected from an alkyl (C1-C3) group, an alkyl (Ci- C3) group substituted with one or more halogen atoms, an alkoxy (C1-C3) group, an alkoxy (C1-C3) group substituted with one or more halogen atoms, cyano; Ri represents alicyclic amines selected from differently substituted azetidine, pyrrolidine, piperidine, azepine, tropane. Compounds of the invention display high affinity for the 5-HT6 receptors and affect receptor constitutive activity. Compounds of the invention are useful for the treatment of cognitive deficits related to neuropsychiatric disorders, dementia associated with neurodegenerative disorders, neuropathic pain, and/or other disorders where modification of the constitutive activity of the 5-HT6 receptor is preferable.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/18 - Bridged systems
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: - providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; - the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: - a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilisation of the emulsion.

IPC Classes  ?

• A61K 8/00 - Cosmetics or similar toiletry preparations
• B01D 11/02 - Solvent extraction of solids

Abstract

The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: - providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; - the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: - a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilisation of the emulsion.

IPC Classes  ?

• B01D 11/02 - Solvent extraction of solids
• A61K 8/00 - Cosmetics or similar toiletry preparations

Abstract

The present invention relates to new compounds that act as inhibitors of metallo-betalactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of bacterial infections. More generally, the present invention finds applications in any field wherein bacteria producing MBL must be removed.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 31/04 - Antibacterial agents
• C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to new compounds that act as inhibitors of metallo-betalactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of bacterial infections. More generally, the present invention finds applications in any field wherein bacteria producing MBL must be removed.

IPC Classes  ?

• C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61P 31/04 - Antibacterial agents
• A61K 31/4196 - 1,2,4-Triazoles

Abstract

The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof

Abstract

Plasmodium falciparum. Also disclosed are pharmaceutical compositions containing such compounds.

IPC Classes  ?

• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• A61P 33/06 - Antimalarials
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols